Finding 1224289 (2025-004)

Material Weakness Repeat Finding
Requirement
H
Questioned Costs
-
Year
2025
Accepted
2026-07-21
Audit: 407580
Organization: HEALTHX PARTNERS INCORPORATED (DC)
Auditor: BDO

AI Summary

  • Core Issue: Costs totaling $32,566 were recorded after the end of the performance period, violating compliance requirements.
  • Impacted Requirements: Noncompliance with §200.309 and §200.344(c) regarding allowable costs and liquidation of obligations.
  • Recommended Follow-Up: Revise internal procedures to better detect out-of-period expenses and consider closing the project in the accounting system to manage post-performance costs.

Finding Text

Internal Controls over Compliance and Compliance with the Period of Performance Compliance Requirement Identification of the Major Federal Program: United States Agency for International Development (USAID) Assistance Listing Number: 98.NoAL Assistance Listing Name: USAID – Cost-Reimbursable Contracts and Other Awards Grant Award Number under the Uniform Guidance Requirements: See Schedule of Findings and Questioned Costs for table. Criteria or Specific Requirement: In accordance with §200.309 Modification to Period of Performance, a non-Federal entity may charge to the Federal award only allowable costs incurred during the period of performance and any costs incurred before the Federal awarding agency or pass-through entity made the Federal award that were authorized by the Federal awarding agency or pass-through entity. Additionally, §200.344(c) Closeout, states that unless the Federal awarding agency or pass-through entity authorizes an extension, a non-Federal entity must liquidate all obligations incurred under the Federal award not later than 120 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award as required by §200.344(b). When used in connection with a non-Federal entity’s utilization of funds under a Federal award, “financial obligations”, as defined in §200.1 Definitions, means orders placed for property, services, contracts, and subawards made, and similar transactions during a given period that require payment by the non-Federal entity during the same or a future period. Condition: During the period of performance completeness testing, we identified $31,281 of costs related to EGPAF and $1,285 related to PSI that were recorded after the period of performance. Questioned Costs: $32,566 of known questioned costs. Context: Our testing of the period of performance compliance requirement was performed by examining whether the expenses selected as part of our testing of allowable costs and allowable activities were incurred within the proper period of performance of the award. Our subsequent testing of additional detailed expenditures identified no further samples that were recorded incorrectly. Cause: HealthXP management has procedures in place to review expenditures to determine the appropriate period of performance; however, those procedures were not performed to a level of detail to identify expenses that were incurred outside the period of the award. Effect: The lack of adherence to the established internal control procedures around the period of performance of the award resulted in noncompliance and questioned costs billed and received that need to be returned to the USAID. Continued noncompliance with federal statutes, regulations, and the provisions of the award agreements could ultimately result in additional disallowed costs for the major program. Repeat Finding: This is not a repeat finding. Recommendation: We recommend management revisit and consider revising their internal procedures around detecting expenditures incurred outside of the period of performance in order to prevent the charging of costs outside of the period of performance of the award. Furthermore, we believe an option would be to close the project within the accounting system, and create a separate project to accumulate any costs incurred after the end of the period of performance. The costs incurred subsequent to the end of the period of performance should be reviewed and approved by individuals at HealthXP’s headquarters. Views of Responsible Officials: HealthXP management agrees with the finding and recommendations set forth within and will provide training to appropriate staff responsible for monitoring expenses on the program. Refer to management’s corrective action plan for additional information.

Corrective Action Plan

Internal Controls over Compliance and Compliance with the Period of Performance Compliance Requirement Contact: Katie Queen Dossinger Title: Chief Operating Officer Phone Number: 202-785-0072 Estimated Completion Date: Ongoing Corrective Action The results of the 2025 audit will be shared with appropriate PSI and EGPAF staff and reinforced through training to ensure adequate attention and clear guidance on the allowability of trailing costs and the unallowability of newly incurred costs.

Categories

Subrecipient Monitoring Period of Performance

Other Findings in this Audit

  • 1224236 2025-001
    Material Weakness Repeat
  • 1224237 2025-001
    Material Weakness Repeat
  • 1224238 2025-001
    Material Weakness Repeat
  • 1224239 2025-001
    Material Weakness Repeat
  • 1224240 2025-001
    Material Weakness Repeat
  • 1224241 2025-001
    Material Weakness Repeat
  • 1224242 2025-001
    Material Weakness Repeat
  • 1224243 2025-001
    Material Weakness Repeat
  • 1224244 2025-001
    Material Weakness Repeat
  • 1224245 2025-001
    Material Weakness Repeat
  • 1224246 2025-005
    Material Weakness Repeat
  • 1224247 2025-001
    Material Weakness Repeat
  • 1224248 2025-001
    Material Weakness Repeat
  • 1224249 2025-001
    Material Weakness Repeat
  • 1224250 2025-001
    Material Weakness Repeat
  • 1224251 2025-001
    Material Weakness Repeat
  • 1224252 2025-001
    Material Weakness Repeat
  • 1224253 2025-001
    Material Weakness Repeat
  • 1224254 2025-001
    Material Weakness Repeat
  • 1224255 2025-001
    Material Weakness Repeat
  • 1224256 2025-001
    Material Weakness Repeat
  • 1224257 2025-001
    Material Weakness Repeat
  • 1224258 2025-001
    Material Weakness Repeat
  • 1224259 2025-001
    Material Weakness Repeat
  • 1224260 2025-001
    Material Weakness Repeat
  • 1224261 2025-001
    Material Weakness Repeat
  • 1224262 2025-001
    Material Weakness Repeat
  • 1224263 2025-001
    Material Weakness Repeat
  • 1224264 2025-001
    Material Weakness Repeat
  • 1224265 2025-001
    Material Weakness Repeat
  • 1224266 2025-001
    Material Weakness Repeat
  • 1224267 2025-001
    Material Weakness Repeat
  • 1224268 2025-001
    Material Weakness Repeat
  • 1224269 2025-001
    Material Weakness Repeat
  • 1224270 2025-001
    Material Weakness Repeat
  • 1224271 2025-001
    Material Weakness Repeat
  • 1224272 2025-001
    Material Weakness Repeat
  • 1224273 2025-004
    Material Weakness Repeat
  • 1224274 2025-001
    Material Weakness Repeat
  • 1224275 2025-001
    Material Weakness Repeat
  • 1224276 2025-001
    Material Weakness Repeat
  • 1224277 2025-001
    Material Weakness Repeat
  • 1224278 2025-001
    Material Weakness Repeat
  • 1224279 2025-001
    Material Weakness Repeat
  • 1224280 2025-001
    Material Weakness Repeat
  • 1224281 2025-001
    Material Weakness Repeat
  • 1224282 2025-001
    Material Weakness Repeat
  • 1224283 2025-001
    Material Weakness Repeat
  • 1224284 2025-001
    Material Weakness Repeat
  • 1224285 2025-001
    Material Weakness Repeat
  • 1224286 2025-001
    Material Weakness Repeat
  • 1224287 2025-001
    Material Weakness Repeat
  • 1224288 2025-001
    Material Weakness Repeat
  • 1224290 2025-005
    Material Weakness Repeat
  • 1224291 2025-003
    Material Weakness Repeat
  • 1224292 2025-002
    Material Weakness Repeat
  • 1224293 2025-003
    Material Weakness Repeat
  • 1224294 2025-003
    Material Weakness Repeat
  • 1224295 2025-003
    Material Weakness Repeat
  • 1224296 2025-003
    Material Weakness Repeat
  • 1224297 2025-003
    Material Weakness Repeat
  • 1224298 2025-003
    Material Weakness Repeat
  • 1224299 2025-005
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
98.U00 USAID/Tanzania's Client-Centered Health Program - HIV and Tuberculosis Northern (C3HP-NIV&TB Northern) $15.41M
98.U00 Global Health Supply Chain (GSHC) - Procurement and Supply Management (PSM) $3.18M
12.350 DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM $2.64M
98.U00 Donated Commodities $2.17M
98.U00 Southern Africa's Attain & Sustain 95-95-95, Present New Infections and Reach All Populations for Epidemic Control (ASPIRE) $1.03M
93.067 GLOBAL AIDS $1.01M
98.001 USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS $894,682
12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT $203,175
98.U00 PMI Prevention of Malaria Through Vector Control $190,245
98.U00 USAID Western Kenya Sanitation (WKSP) $146,407
98.U00 Ethiopia Urban Water, Sanitation and Hygiene (WASH) Activity $123,146
98.U00 USAID West Africa Municipal Wash (MuniWASH) $66,273
98.U00 USAID WASH Services $60,267
98.U00 WCA_USAID_Transform IDIQ $1,285